{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:41:05Z","timestamp":1792269665924,"version":"4.4.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.cld.2007.11.011","type":"journal-article","created":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T08:46:43Z","timestamp":1201855603000},"page":"81-96","source":"Crossref","is-referenced-by-count":13,"title":["Role of Methotrexate in the Treatment of Chronic Cholestatic Disorders"],"prefix":"10.1016","volume":"12","author":[{"given":"Kerri","family":"Novak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Swain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2007.11.011_bib1","series-title":"Kelley's textbook of rheumatology","first-page":"996","article-title":"Methotrexate, leflunomide, and combination therapies","author":"O'Dell","year":"2005"},{"key":"10.1016\/j.cld.2007.11.011_bib2","first-page":"27","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"26","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2007.11.011_bib3","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1056\/NEJMoa021359","article-title":"Methotrexate versus cyclosporine in moderate to severe chronic plaque psoriasis","volume":"349","author":"Heydendael","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2007.11.011_bib4","article-title":"Methotrexate for the induction of remission of refractory Crohn's disease","volume":"1","author":"Alfadhi","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cld.2007.11.011_bib5","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn's disease","volume":"332","author":"Feagan","year":"1995","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cld.2007.11.011_bib6","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0889-857X(05)70358-6","article-title":"The mechanism of action of methotrexate","volume":"23","author":"Cronstein","year":"1997","journal-title":"Rheum Dis Clin North Am"},{"issue":"8","key":"10.1016\/j.cld.2007.11.011_bib7","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/rheumatology\/34.8.747","article-title":"Effect of methotrexate alone or in combination with suphasalazine on the production and circulating concentrations of cytokines and their antagonists: longitudinal evaluation in patients with rheumatoid arthritis","volume":"34","author":"Barrera","year":"1995","journal-title":"Br J Rheumatol"},{"issue":"S31","key":"10.1016\/j.cld.2007.11.011_bib8","first-page":"S179","article-title":"Methotrexate as the \u201canchor drug\u201d for the treatment of early rheumatoid arthritis","volume":"21","author":"Pincus","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.cld.2007.11.011_bib9","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clim.2004.09.001","article-title":"The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules","volume":"114","author":"Johnston","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.cld.2007.11.011_bib10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/ard.59.4.311","article-title":"Response to methotrexate in early rheumatoid arthritis is associated with a decrease in T cell derived tumour necrosis factor-alpha, increase of interleukin 10 and predicted by the initial concentration of interleukin 4","volume":"59","author":"Rudwaleit","year":"2000","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.cld.2007.11.011_bib11","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2003.014738","article-title":"Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis (rheumatic disease research)","volume":"63","author":"Kraan","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cld.2007.11.011_bib12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2249.2007.03441.x","article-title":"The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders","volume":"149","author":"Barsky","year":"2007","journal-title":"Clin Experim Immunol"},{"issue":"28","key":"10.1016\/j.cld.2007.11.011_bib13","doi-asserted-by":"crossref","first-page":"11742","DOI":"10.1073\/pnas.0610812104","article-title":"TNF-induced structural joint damage is mediated by IL-1","volume":"104","author":"Zwerina","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cld.2007.11.011_bib14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1440-1746.2002.02672.x","article-title":"Tumor necrosis factor-\u03b1 and transforming growth factor-\u03b2 reflect severity of liver damage in primary biliary cirrhosis","volume":"17","author":"Neuman","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2007.11.011_bib15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1136\/gut.48.3.397","article-title":"HLA and cirrhosis: associations with disease progression and disease susceptibility","volume":"48","author":"Donaldson","year":"2001","journal-title":"GUT"},{"key":"10.1016\/j.cld.2007.11.011_bib16","first-page":"S86","article-title":"Methotrexate inhibits IL-1 activity","volume":"29","author":"Miller","year":"1986","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cld.2007.11.011_bib17","first-page":"518","article-title":"Synthesis of interleukin-1\u03b2 in primary biliary cirrhosis: relationship to treatment with methotrexate or colchicines and disease progression","volume":"22","author":"Miller","year":"1995","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2007.11.011_bib18","first-page":"261","article-title":"Safety of methotrexate in rheumatoid arthritis: a retrospective cohort study in clinical practice","volume":"58","author":"La Montagna","year":"2006","journal-title":"Rheumatism"},{"issue":"2","key":"10.1016\/j.cld.2007.11.011_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00044011-200626020-00001","article-title":"Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis","volume":"26","author":"Tilling","year":"2006","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.cld.2007.11.011_bib20","article-title":"Methotrexate for the treatment of rheumatoid arthritis","volume":"2","author":"Suarez-Almazor","year":"1997","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cld.2007.11.011_bib21","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0002-9343(05)80060-9","article-title":"Methotrexate and histologic hepatic abnormalities: a meta-analysis","volume":"90","author":"Whiting-O'Keefe","year":"1991","journal-title":"Am J Med"},{"issue":"21","key":"10.1016\/j.cld.2007.11.011_bib22","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1056\/NEJM199611213352107","article-title":"Primary biliary cirrhosis","volume":"335","author":"Kaplan","year":"1996","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cld.2007.11.011_bib23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1572-0241.2001.03446.x","article-title":"Genetic and familial considerations of primary biliary cirrhosis","volume":"95","author":"Tanaka","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2007.11.011_bib24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1136\/gut.48.3.397","article-title":"HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility","volume":"48","author":"Donaldson","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.cld.2007.11.011_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/s-2007-1007189","article-title":"Cytokines in primary biliary cirrhosis","volume":"17","author":"Berg","year":"1997","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cld.2007.11.011_bib26","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1136\/gut.31.8.938","article-title":"Tumor necrosis factor, cholestatic jaundice and chronic liver disease","volume":"31","author":"Jones","year":"1990","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cld.2007.11.011_bib27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2249.2006.03293.x","article-title":"Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumor necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatits C","volume":"148","author":"Pelli","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.cld.2007.11.011_bib28","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1046\/j.1365-2249.1996.d01-759.x","article-title":"mRNA expression in the liver of patients with primary biliary cirrhosis and chronic hepatitis B","volume":"105","author":"Mullin","year":"1996","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.cld.2007.11.011_bib29","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/hep.510250402","article-title":"In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset","volume":"25","author":"Harada","year":"1997","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2007.11.011_bib30","first-page":"372","article-title":"Promotyion of leukocytye transendothelial cell migration by chemokines derived from human biliary epithelial cells in vitro","volume":"109","author":"Morland","year":"1997","journal-title":"Proc Assoc Am Physicians"},{"key":"10.1016\/j.cld.2007.11.011_bib31","first-page":"1106","article-title":"Blood and liver infiltrating lymphocytes in primary biliary cirrhosis: Increased in activated T and natural killer cells and recruitment of primed memory T cells","volume":"13","author":"Bjorkland","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2007.11.011_bib32","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1034\/j.1600-0528.2002.00021h.x","article-title":"Autoreactive responses to pyruvate dehydrogenase complex in the pathogenesis of primary biliary cirrhosis","volume":"174","author":"Yeaman","year":"2000","journal-title":"Immunol Rev"},{"key":"10.1016\/j.cld.2007.11.011_bib33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1440-1827.2006.01913.x","article-title":"Characterization of biliary intra-epithelial lymphocytes at different anatomic levels of intrahepatic bile ducts under normal and pathologic conditions: numbers of CD4 + CD28- intra-epitheliual lymphocytes are increased in primary biliary cirrhosis","volume":"56","author":"Isse","year":"2006","journal-title":"Pathol Int"},{"key":"10.1016\/j.cld.2007.11.011_bib34","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1034\/j.1600-0676.2001.021004272.x","article-title":"Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis","volume":"21","author":"Furtwaengler","year":"2001","journal-title":"Liver"},{"key":"10.1016\/j.cld.2007.11.011_bib35","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1053\/gast.2002.36020","article-title":"Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer","volume":"123","author":"Kita","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2007.11.011_bib36","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.21123","article-title":"Liver targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis","volume":"43","author":"Lan","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2007.11.011_bib37","article-title":"Heath-related quality of life in Chinese patients with primary biliary cirrhosis","author":"Wong","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2007.11.011_bib38","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1053\/he.2000.5984","article-title":"AASLD practice guidelines. Management of primary biliary cirrhosis","volume":"31","author":"Heathcote","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2007.11.011_bib39","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastro"},{"key":"10.1016\/j.cld.2007.11.011_bib40","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0016-5085(97)70239-7","article-title":"Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei","volume":"112","author":"Setchell","year":"1997","journal-title":"Gastro"},{"key":"10.1016\/j.cld.2007.11.011_bib41","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","article-title":"The effect of ursodeoxycholic acid on liver fibrosis in primary biliary cirrhosis","volume":"32","author":"Capechot","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2007.11.011_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/hep.21795","article-title":"Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study","author":"Jackson","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2007.11.011_bib43","first-page":"A1094","article-title":"Sustained remission of primary biliary cirrhosis with methotrexate","volume":"S108","author":"Kaplan","year":"1995","journal-title":"Gastro"},{"key":"10.1016\/j.cld.2007.11.011_bib44","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/0016-5085(91)90085-Y","article-title":"Treatmentof primary biliary cirrhosis with low-dose weekly methotrexate","volume":"101","author":"Kaplan","year":"1991","journal-title":"Gastro"},{"issue":"2","key":"10.1016\/j.cld.2007.11.011_bib45","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/gast.1999.0029900395","article-title":"Methotrexate improves biochemical test in patients with primary biliary cirrhosis who respond incompletely to ursodeoxycholic acid","volume":"117","author":"Bonis","year":"1999","journal-title":"Gastro"},{"key":"10.1016\/j.cld.2007.11.011_bib46","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/hep.20103","article-title":"A randomized controlled trial of colchicines plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten year results","volume":"39","author":"Kaplan","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2007.11.011_bib47","first-page":"1158","article-title":"The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the result of a pilot study","volume":"22","author":"Lindor","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2007.11.011_bib48","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/17843286.1996.11718480","article-title":"Combined treatment with methotrexate and ursodeoxycholic acid in non-cirrhotic primary biliary cirrhosis","volume":"51","author":"Van Steenbergen","year":"1996","journal-title":"Acta Clin Belg"},{"issue":"1","key":"10.1016\/j.cld.2007.11.011_bib49","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0168-8278(01)80199-9","article-title":"Ursodeoxycholic acid and methotrexate for primary biliary cirrhosis","volume":"34","author":"Copaci","year":"2001","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2007.11.011_bib50","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0168-8278(97)80294-2","article-title":"The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone","volume":"27","author":"Gonzalez-Koch","year":"1997","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2007.11.011_bib51","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/hep.20897","article-title":"Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis","volume":"42","author":"Combes","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2007.11.011_bib52","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1572-0241.2003.07173.x","article-title":"Methotrexate therapy for primary biliary cirrhosis","volume":"98","author":"Bach","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2007.11.011_bib53","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/hep.20188","article-title":"Trials in primary biliary cirrhosis: need for the right drugs at the right time","volume":"39","author":"Poupon","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2007.11.011_bib54","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/gast.1999.0029900400","article-title":"Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo controlled trial","volume":"117","author":"Hendrickse","year":"1999","journal-title":"Gastro"},{"key":"10.1016\/j.cld.2007.11.011_bib55","article-title":"Methotrexate for primary biliary cirrhosis","volume":"3","author":"Gong","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.cld.2007.11.011_bib56","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1572-0241.2000.01857.x","article-title":"Impact of fatigue on the quality of life of patients with primary biliary cirrhosis","volume":"95","author":"Huet","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2007.11.011_bib57","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","article-title":"Randomized controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis","volume":"354","author":"Goulis","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2007.11.011_bib58","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/gast.1997.v113.pm9322521","article-title":"Oral natrexone treatment for cholestastic pruritus: a double blind, placebo controlled study","volume":"113","author":"Wolfhagen","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2007.11.011_bib59","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/0016-5085(88)90442-8","article-title":"Treatment of pruritus in primary biliary cirrhosis with rifampin","volume":"94","author":"Ghent","year":"1988","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2007.11.011_bib60","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11938-004-0009-1","article-title":"The treatment of the pruritus of cholestasis","volume":"7","author":"Bergassa","year":"2004","journal-title":"Curr Treat Options Gastroenterol"},{"key":"10.1016\/j.cld.2007.11.011_bib61","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/hep.1840080440","article-title":"Liver transplantation: an overview","volume":"8","author":"Maddrey","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2007.11.011_bib62","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/gut.2005.080317","article-title":"Four year follow-up of fatigue in a geographically defined primary biliary cirrhosis patient cohort","volume":"55","author":"Jones","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.cld.2007.11.011_bib63","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1155\/2006\/624832","article-title":"Fatigue in liver disease: pathophysiology and clinical management","volume":"20","author":"Swain","year":"2006","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.cld.2007.11.011_bib64","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/gut.2003.025155","article-title":"Fatigue in chronic cholestasis","volume":"53","author":"Milkiewicz","year":"2004","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.cld.2007.11.011_bib65","first-page":"295","article-title":"Pilot study of low dose oral methotrexate treatment for primary biliary cirrhosis","volume":"91","author":"Bergasa","year":"1996","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2007.11.011_bib66","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0168-8278(05)80004-2","article-title":"Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone","volume":"18","author":"Buscher","year":"1993","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2007.11.011_bib67","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1365-2036.2006.03048.x","article-title":"Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy","volume":"24","author":"Babatin","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2007.11.011_bib68","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/hep.510280616","article-title":"Augmented interleukin-1\u03b2\u2013induced depression of locomoter activity in cholestatic rats","volume":"28","author":"Swain","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2007.11.011_bib69","series-title":"The molecular pathogenesis of cholestasis","article-title":"Molecular pathophysiology of fatigue and pruritus","author":"Swain","year":"2003"},{"key":"10.1016\/j.cld.2007.11.011_bib70","article-title":"Methotrexate as a steroid sparing agent for asthma in adults","volume":"2","author":"Davis","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cld.2007.11.011_bib71","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.gastro.2003.07.011","article-title":"Incidence, clinical spectrum and outcome of primary sclerosing cholangitis in a United States community","volume":"125","author":"Bambha","year":"2003","journal-title":"Gastro"},{"issue":"1","key":"10.1016\/j.cld.2007.11.011_bib72","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2006-933559","article-title":"Etiopathogenesis of primary sclerosing cholangitis","volume":"26","author":"O'Mahony","year":"2006","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cld.2007.11.011_bib73","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/gut.49.1.131","article-title":"Tumor necrosis factor-alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis","volume":"49","author":"Bo","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.cld.2007.11.011_bib74","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.autrev.2004.09.003","article-title":"The immunobiology of primary sclerosing cholangitis","volume":"4","author":"Aoki","year":"2005","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.cld.2007.11.011_bib75","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hep.21337","article-title":"Primary sclerosing cholangitis: summary of a workshop","volume":"44","author":"LaRusso","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2007.11.011_bib76","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1053\/gast.2001.27965","article-title":"A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis","volume":"121","author":"Michell","year":"2001","journal-title":"Gastro"},{"key":"10.1016\/j.cld.2007.11.011_bib77","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/j.1572-0241.2001.03777.x","article-title":"High-dose ursodeoxycholic acid as therapy for primary sclerosing cholagitis","volume":"96","author":"Harnois","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2007.11.011_bib78","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5 year, multicenter, randomized controlled trial","volume":"129","author":"Olsson","year":"2005","journal-title":"Gastro"},{"key":"10.1016\/j.cld.2007.11.011_bib79","first-page":"57","article-title":"The combination of prednisone and colchicines in patients with primary sclerosing cholangitis","volume":"86","author":"Lindor","year":"1991","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2007.11.011_bib80","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1572-0241.2005.40484.x","article-title":"Mycophenylate mofetil for the treatment of primary sclerosing cholangitis","volume":"100","author":"Talkwalkar","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2007.11.011_bib81","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/0016-5085(95)90220-1","article-title":"Colchicine treatment of primary sclerosing cholangitis","volume":"108","author":"Olsson","year":"1995","journal-title":"Gastro"},{"issue":"3","key":"10.1016\/j.cld.2007.11.011_bib82","first-page":"455","article-title":"Tacrolimus, a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial","volume":"90","author":"Van Thie","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2007.11.011_bib83","doi-asserted-by":"crossref","first-page":"231","DOI":"10.7326\/0003-4819-106-2-231","article-title":"Primary sclerosing cholangitis and low-dose oral pulse methotrexate therapy. Clinical and histologic response","volume":"106","author":"Kaplan","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cld.2007.11.011_bib84","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/0016-5085(94)90610-6","article-title":"A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis","volume":"106","author":"Knox","year":"1994","journal-title":"Gastro"},{"issue":"3","key":"10.1016\/j.cld.2007.11.011_bib85","first-page":"511","article-title":"Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study","volume":"91","author":"Lindor","year":"1996","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.cld.2007.11.011_bib86","first-page":"1886","article-title":"Pneumocytis carinii pneumonia complicating methotrexate treatment of primary sclerosing cholangitis","volume":"90","author":"Duerksen","year":"1995","journal-title":"Am J Gastroenterol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326107001201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326107001201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T12:18:51Z","timestamp":1557231531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326107001201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S1089326107001201"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2007.11.011","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}